GlassScriptPhysician profile
Edgard I Wehbe
NPI 1851513287
$48,986.38
in general payments reported to CMS, 2019-2025
31 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $5,913 · 2021: $5,510 · 2022: $30K · 2023: $5,790 · 2024: $655 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,906 · Food and Beverage: $1,891 · Consulting Fee: $272 · Education: $0.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,906.00 |
| Food and Beverage | $1,890.85 |
| Consulting Fee | $272.00 |
| Education | $0.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32,902.48 | 2022-2025 | |
| Vifor Pharma, INC. | $12,911.64 | 2019-2022 | |
| Amgen INC. | $375.54 | 2019-2025 | Tavneos, Krystexxa |
| Mallinckrodt Enterprises LLC | $275.33 | 2019 | |
| Opko Pharmaceuticals, LLC | $240.95 | 2019-2024 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $208.98 | 2021-2025 | |
| Akebia Therapeutics INC | $205.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.32 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $170.69 | 2022-2024 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $156.91 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $148.27 | 2022-2025 | Benlysta |
| Medtronic, INC. | $122.65 | 2025 | Symplicity G3 |
| Novo Nordisk INC | $116.02 | 2022-2024 | Ozempic, Rybelsus |
| Mallinckrodt Hospital Products INC. | $110.07 | 2022-2024 | Terlivaz, Acthar |
| Scpharmaceuticals INC. | $104.86 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $104.52 | 2024-2025 | Ibsrela |
| Shield Therapeutics INC | $86.07 | 2025 | |
| Shire North American Group INC | $73.49 | 2019 | |
| Fresenius USA Marketing, INC. | $62.41 | 2019-2024 | Nxstage System One, Liberty Select Cycler |
| Takeda Pharmaceuticals U.S.A., INC. | $53.14 | 2022-2023 | Gattex |
| Travere Therapeutics, INC. | $49.65 | 2019-2024 | |
| Pharmacosmos Therapeutics INC. | $42.78 | 2022 | |
| Daiichi Sankyo INC. | $41.65 | 2022 | |
| Genzyme Corporation | $38.61 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $36.43 | 2019 | |
| Horizon Therapeutics Plc | $32.70 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $26.36 | 2019 | |
| Kyowa Kirin, INC. | $23.98 | 2023 | Crysvita |
| Alnylam Pharmaceuticals INC. | $23.34 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.36 | 2024 | Keveyis |
| Aurinia Pharma U.S., INC. | $19.42 | 2023 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgard Wehbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.